Business Context and Reporting Period
Company: Kitov Pharmaceuticals Holdings Ltd. (f/k/a Mainrom Line Logistics Ltd.), an Israeli biopharmaceutical company.
Reporting Period: Fiscal year ended December 31, 2016.
Business Overview: The Company is a development-stage biopharmaceutical firm focused on two primary therapeutic candidates: KIT-302, a combination drug for osteoarthritis pain and hypertension (completed Phase III trials), and NT219, an oncology candidate acquired via the January 2017 acquisition of a majority stake in TyrNovo Ltd. The Company has no commercial revenue and relies on equity financing and potential licensing deals.
Key Financial Metrics
| Metric (in thousands USD) | 2016 | 2015 |
|---|---|---|
| Revenue | $0 | $0 |
| Research & Development Expenses | $4,180 | $2,560 |
| General & Administrative Expenses | $3,003 | $1,509 |
| Operating Loss | $(7,183) | $(4,069) |
| Financing Expense, Net | $(4,942) | $(133) |
| Net Loss for the Period | $(12,125) | $(4,202) |
| Cash and Cash Equivalents (Year End) | $6,758 | $10,558 |
| Working Capital | $13,625 | $9,606 |
| Total Equity | $13,385 | $9,429 |
| Accumulated Deficit | $(26,200) | $(14,054) |
Note: The 2016 financing expense includes a non-cash charge of approximately $5.0 million related to the change in fair value of derivative instruments (Series A Warrants).
Material Changes vs. Prior Period
- Increased Operating Loss: Operating loss widened by 76% to $7.2 million in 2016 from $4.1 million in 2015. This was driven by a 63% increase in R&D expenses (due to PK studies, NDA preparation, and a new renal function trial) and a 99% increase in G&A expenses (due to salaries and NASDAQ listing costs).
- Derivative Valuation Impact: The net loss for 2016 was significantly impacted by a $5.0 million non-cash expense from the fair value adjustment of public warrants, which included anti-dilution protection that expired in November 2016.
- Liquidity Position: Cash and cash equivalents decreased by approximately $3.8 million to $6.8 million, reflecting higher operational burn rates despite a $12.0 million follow-on equity offering in July 2016.
Guidance, Outlook, Risks, and Unusual Items
Outlook and Guidance
- KIT-302: The Company plans to submit a New Drug Application (NDA) to the FDA in Q2 2017, anticipating marketing approval in 2018. A renal function clinical trial is ongoing to validate beneficial effects on kidney function.
- NT219: Following the acquisition of TyrNovo, the Company expects to complete CMC and preclinical toxicology studies in 2017, with an IND submission anticipated in 2018.
- Capital Needs: Management believes current cash is sufficient for operations through at least the next 12 months but expects to require substantial additional capital to complete development and commercialization.
Material Risks and Contingencies
- Regulatory Investigation: The Israeli Securities Authority (ISA) initiated a formal investigation in February 2017 regarding the Company's public disclosures concerning the Phase III clinical trial of KIT-302. This poses a risk to the FDA approval process and could result in fines or penalties.
- Legal Proceedings: Multiple class action lawsuits have been filed in Israel and the U.S. related to the ISA investigation and the 2015 IPO. The Company faces potential significant legal defense costs and damages.
- Internal Control Weakness: Management identified a material weakness in internal controls over financial reporting regarding the review of complex transactions, which led to an accounting error in equity and derivative instruments corrected prior to filing.
- Government Grants (TyrNovo): TyrNovo's technology is funded by Israeli government grants (OCS/Innovation Authority), which impose restrictions on manufacturing outside Israel and require royalty payments on future sales, potentially complicating partnerships or acquisitions.
Investor Verification Checklist
- ISA Investigation Status: Verify the current status of the Israeli Securities Authority investigation and any potential impact on the FDA's review of the KIT-302 NDA.
- Cash Runway: Confirm the sufficiency of the $6.8 million cash balance to fund operations through the anticipated 2018 approval timeline, considering the high burn rate.
- Derivative Liability: Review the terms of the public warrants and the potential for future fair value adjustments to impact net income.
- Internal Controls Remediation: Assess the progress of remediation plans for the identified material weakness in internal financial controls.
- TyrNovo Integration: Evaluate the financial and operational integration of TyrNovo, including the impact of Israeli government grant restrictions on future commercialization strategies.